According to a new systematic review, placebo treatment in clinical trials of migraine prophylaxis results in responder rates ranging from 0–56%, probably owing to variable combinations of spontaneous improvement and genuine placebo effects. Clinicians who treat patients with migraine should be aware of the potential nonspecific effects of any treatment modality.
This is a preview of subscription content, log in via an institution to check access.
References
Meissner, K. et al. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2013.10391.
Krogsbøll, L. T., Hróbjartsson, A. & Gøtzsche, P. C. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med. Res. Methodol. 9, 1 (2009).
Linde, M., Mulleners, W. M., Chronicle, E. P. & McCrory, D. C. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews, Issue 6. Art. No.: CD010610 http://dx.doi.org/10.1002/14651858.CD010610.
Macedo, A., Baños, J.-E. & Farré, M. Placebo response in the prophylaxis of migraine: a meta-analysis. Eur. J. Pain 12, 68–75 (2008).
Patel, S. M. et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol. Motil. 17, 332–340 (2005).
Linde, K. et al. Acupuncture for patients with migraine: a randomized controlled trial. JAMA 293, 2118–2125 (2005).
de Craen, A. J., Tijssen, J. G., de Gans, J. & Kleijnen, J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J. Neurol. 247, 183–188 (2000).
Diener, H.-C. et al. Topiramate in migraine prophylaxis—results from a placebo-controlled trial with propranolol as an active control. J. Neurol. 251, 943–950 (2004).
Tfelt-Hansen, P. et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 32, 6–38 (2012).
Pradalier, A. et al. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs 18, 1149–1163 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Tfelt-Hansen, P., Hougaard, A. Differential effects of placebos in migraine clinical trials. Nat Rev Neurol 10, 10–11 (2014). https://doi.org/10.1038/nrneurol.2013.255
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.255
- Springer Nature Limited